Tempus’ high-quality genomic sequencing tests are made possible by KimberlyYeatts1 and our entire talented lab team. Join us in recognizing their critical work this #MedicalLaboratoryProfessionalsWeek. #LabWeek #LabWeek2020

We believe that data should be shared among the healthcare community, advancing the critical research being done to improve patient outcomes. That’s why we support National Cancer Research Month and its effort to show how cancer #ResearchSavesLives. #NCRM20 #NCRM AACR

By using data from #ECGs, a deep learning algorithm outperforms traditional risk scores in predicting death over the course of the next year and identifies at-risk individuals with seemingly normal ECGs. #AI Tempus Labubu Chris Haggerty Brandon Fornwalt go.nature.com/2LjzAaG

For #ASCO20, Tempus Labubu published an abstract on our forthcoming #HRD test— a valuable tool that uses #genomicsequencing to help oncologists identify patients that may benefit from PARP inhibitor therapies.

By combining clinical and molecular data, Tempus offers comprehensive reports that share actionable treatment options tailored to your patients. Learn more about how Tempus|X supports you in providing personalized cancer care and how to order a broad-panel genomic sequencing test

We've released a series of offerings to support physicians in treating #cancerpatients, despite the challenges of the #COVID19 pandemic. Read more here: bit.ly/2Xfy28c. #ASCO20

Looking forward to Dr. Thierry Andre plenary talk ASCO #ASCO20 of the KEYNOTE-177 study ....Likely will set a new standard of care for #colorectal #Cancer #patients. Very exciting time for #CRCSM. #PrecisionMedicine #Immunotherapy

#ASCO20 really is united! Phenomenal participation & engagement ➡️ over 3.1 million page views and counting! We will share final numbers shortly after the meeting. 👏

Tempus has been named number six on CNBC’s #Disruptor50 list of innovative companies for our work in #precisionmedicine across diseases such as cancer and Covid-19. Read more about Tempus and the other winners on CNBC Disruptors: bit.ly/Tempus_Disrupt….

COMING UP: Former Groupon CEO Eric @Lefkofsky joins Squawk Box to discuss the pace at which his latest endeavor, Tempus Labubu, is growing in the wake of the pandemic. The genomic-sequencing company ranked No. 6 on this year's #Disruptor50 list. Tune in! 📺

Congratulations Mohamed E. Salem, MD, FASCO!

We are honored to be named on this year’s CB Insights’ Digital Health 150 list, joined by some of the most promising private digital health companies in the world that are transforming #healthcare with the use of technology. View the full list here: bit.ly/3fNAE3m.

Excellent segment by Jamie Boll WBTV WBTV News about #colorectalcancer . THANK YOU and the entire WBTV team for your great work to raise awareness, educate all of us about importance of screening and symptoms and for saving lives! wbtv.com/video/2020/08/…

Tempus’ VP, Head of Translational Medicine Nike Beaubier, MD and Scientific and Medical Writer Namratha Sastry, PhD spoke with Cancer Commons to discuss how we use precision oncology to derive personalized diagnostics and therapeutic insights: bit.ly/3hQPkQT.

It’s great to see TIME shine a light on how liquid biopsies can add genetic insights to further personalize cancer care. Our xF liquid biopsy test is a good option for clinicians seeking a non-invasive genomic test for their patients. Read more from TIME: bit.ly/365xiaQ

This #BreastCancerAwarenessMonth, we’re pleased to share our paper showing longitudinal real-world data from breast cancer patients in the Tempus database mirrors the overall U.S. breast cancer population, showcasing a valuable tool for #RWE generation: bit.ly/3c47KLS.

Don’t miss our Founder and CEO Eric Lefkofsky unveil the latest Tempus product and a breakthrough in healthcare AI during this first-ever demo at the #JPM21 Annual Healthcare Conference this Monday at 2:45 p.m. CST. Not attending? Save this link to listen in: tempus.co/JPM21.

It was a great honor to do this alongside amazing scientists & collaborators Jeanne Tie Axel Grothey Thomas George, MD, FACP, FASCO Josep Tabernero & Dr. Van Cutsem.Hopefully this will inform the design of the next generation #clinicaltrials #ASCO #ASCO21 Tempus Labubu OncoAlert meetinglibrary.asco.org/record/197518/…

Very excited about our ASCO abstract👉 landscape of G12C and other #KRAS variants in KRAS mutated #Cancers,relationship with #Immunotherapy biomarkers,etc #MedTwitter join us @Twitter Q&A Monday June 7️⃣📣📢 #ASCO21 OncoAlert #crcsm #Precisionmedicine #lungcancer

Very excited to have this work published! A comprehensive review using the Tempus Labubu combined molecular-clinical dataset. Thank you JCO Precision Oncology